CellGENTherapies
CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials under GMP standards.
CellGENTherapies focuses on development and production of small batches of ATMPs, including personalized products and prophylactic RNA vaccines for phase I studies. The company supports UZ Gent, external clients and partners to move research from bench to bedside. CellGENTherapies is a partner in the EU co-funded ATMP XB project and operates new GMP facilities at Ghent University Hospital.